Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Published Online
on June 22, 2009

Circulation. 2009
Published online before print June 22, 2009, doi: 10.1161/CIRCULATIONAHA.108.824581
A more recent version of this article appeared on July 7, 2009
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
120/1/35    most recent
CIRCULATIONAHA.108.824581v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Linssen, G. C.M.
Right arrow Articles by Voors, A. A.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Linssen, G. C.M.
Right arrow Articles by Voors, A. A.
Related Collections
Right arrow Cardio-renal physiology/pathophysiology
Right arrow Other heart failure
Right arrow Congestive
Right arrow Other diagnostic testing
Right arrowRelated Article

Submitted on September 26, 2008
Accepted on May 1, 2009

Urinary N-Terminal Prohormone Brain Natriuretic Peptide Excretion in Patients With Chronic Heart Failure

Gerard C.M. Linssen MD, Kevin Damman MD, PhD, Hans L. Hillege MD, PhD, Gerjan Navis MD, PhD, Dirk J. van Veldhuisen MD, PhD, and Adriaan A. Voors MD, PhD*

From the Departments of Cardiology (G.C.M.L., K.D., H.L.H., D.J.v.V., A.A.V.) and Internal Medicine/Division of Nephrology (G.N.), University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.

* To whom correspondence should be addressed. E-mail: a.a.voors{at}thorax.umcg.nl.

Background—Urinary excretion is currently regarded as the main mechanism of elimination of N-terminal prohormone brain natriuretic peptide (NT-proBNP). The clinical implications and the value of measurement of urinary NT-proBNP in patients with heart failure are largely unknown.

Methods and Results—We studied 94 patients (age, 58±11 years; 79% men) with chronic heart failure (CHF) and 20 age- and sex-matched healthy control subjects. Glomerular filtration rate and effective renal plasma flow were measured as clearance of 125I-iothalamate and 131I-hippuran, respectively. NT-proBNP levels were determined in both plasma and 24-hour urine collections. Mean left ventricular ejection fraction of CHF patients was 0.28±0.09. Plasma NT-proBNP levels were higher in CHF patients compared with control subjects (median, 547 versus 41 pg/mL; P<0.001). Urinary NT-proBNP excretion, however, was substantially lower in CHF patients (median, 0.13 versus 2.3 mL/min; P<0.001). Urinary NT-proBNP excretion was independent of estimated glomerular filtration rate. In both CHF patients and control subjects, there was a strong and inverse relation between plasma NT-proBNP concentrations and urinary NT-proBNP excretion (r=-0.72 and r=-0.65 respectively; both P<0.001). Decreased renal plasma flow in CHF was significantly associated with a lower excretion of NT-proBNP (P=0.026).

Conclusions—Urinary NT-proBNP excretion is lower in patients with CHF compared with control subjects and is inversely related to plasma NT-proBNP. Urinary NT-proBNP is associated with renal plasma flow but not with estimated glomerular filtration rate. Elevated levels of plasma NT-proBNP in patients with CHF might be explained not only by myocardial stress but also by a marked decrease in urinary excretion.


Key words: heart failure • kidney • natriuretic peptides


Related Article:

Circulation: Clinical Summaries
Circulation 2009 120: 1-2. [Extract] [Full Text]